Marathon Asset Management Ltd lowered its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 6.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 715,170 shares of the biopharmaceutical company's stock after selling 46,981 shares during the period. Marathon Asset Management Ltd owned 0.12% of Royalty Pharma worth $18,243,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the business. Brooklyn Investment Group boosted its position in shares of Royalty Pharma by 1,006.9% in the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 876 shares during the period. Allworth Financial LP boosted its holdings in shares of Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 877 shares during the period. Riverview Trust Co grew its position in shares of Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 1,186 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Royalty Pharma by 362.7% in the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 943 shares during the period. Finally, Fifth Third Bancorp raised its position in Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 997 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, TD Cowen raised Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Royalty Pharma presently has an average rating of "Buy" and an average target price of $41.60.
Read Our Latest Research Report on Royalty Pharma
Royalty Pharma Trading Down 1.5 %
RPRX stock traded down $0.49 during midday trading on Thursday, hitting $33.28. The stock had a trading volume of 2,367,388 shares, compared to its average volume of 4,452,269. The firm has a market cap of $19.18 billion, a PE ratio of 22.95, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The company's 50-day moving average price is $30.57 and its 200 day moving average price is $28.32.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, equities research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.
Royalty Pharma Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.64%. The ex-dividend date is Friday, February 21st. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. Royalty Pharma's payout ratio is 60.69%.
About Royalty Pharma
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Stories
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
